[Neuropsychiatric adverse effects attributed to use of oxybutynin].
Since 1988, the Netherlands Pharmacovigilance Foundation Lareb and the Inspectorate for Health Care have received 17 reports of patients with neuropsychiatric adverse reactions attributed to the use of oxybutynin hydrochloride. These concerned 6 males and 11 females and 6 out of the 17 patients were children under the age of 13. In all cases patients had been treated according to a normal dosage regimen. Complaints included hallucinations, psychosis, concentration and orientation problems, apathy, listlessness, agitation, drowsiness and sleepiness. Symptoms improved or disappeared in all patients after dose reduction or withdrawal of oxybutynin.
t'Veld
B A
BA
Erasmus Universiteit, afd. Epidemiologie en Biostatistiek, Rotterdam.
Kwee-Zuiderwijk
W J
WJ
van Puijenbroek
E P
EP
Stricker
B H
BH
D000368:Aged; D000369:Aged, 80 and over; D002648:Child; D004775:Enuresis / Q000188:drug therapy; D005260:Female; D006801:Humans; D008297:Male; D008333:Mandelic Acids / Q000009:adverse effects*; D001523:Mental Disorders / Q000139:chemically induced*; D010276:Parasympatholytics / Q000009:adverse effects*; D014549:Urinary Incontinence / Q000188:drug therapy
D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin
Neuropsychiatrische bijwerkingen toegeschreven aan het gebruik van oxybutynine.